Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters
Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"
Aura Biosciences Completes $40 Million Series D Financing
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors
Celgene to acquire Impact Biomedicines, adding Fedratinib to its pipeline of novel therapies for hematologic malignancies
All rights reserved © Medicxi, 2019